Results 81 to 90 of about 1,816 (169)

Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b

Gut and Liver, 2018
Background/AimsChanges in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years.
Takeshi Chida, Kazuhito Kawata, Kazuyoshi Ohta, Erika Matsunaga, Jun Ito, Shin Shimoyama, Satoru Yamazaki, Hidenao Noritake, Tetsuro Suzuki, Takafumi Suda, Yoshimasa Kobayashi   +10 more
doaj   +1 more source

Modulation of chimeric antigen receptor surface expression by a small molecule switch

BMC Biotechnology, 2019
Background Engineered therapeutic cells have attracted a great deal of interest due to their potential applications in treating a wide range of diseases, including cancer and autoimmunity.
Alexandre Juillerat, Diane Tkach, Brian W. Busser, Sonal Temburni, Julien Valton, Aymeric Duclert, Laurent Poirot, Stéphane Depil, Philippe Duchateau   +8 more
doaj   +1 more source

Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China

, 2018
Aim: To evaluate the cost–effectiveness of the novel all-oral direct-acting antiviral regimen daclatasvir + asunaprevir (DUAL), versus interferon-based regimens for the treatment of chronic hepatitis C virus genotype 1b infection.
Peter Feng Wang, Gail D Wygant, Jason Gordon, Thomas Ward, Jing Yan, Wen Chen, Mai Ping Tan   +6 more
core   +1 more source

Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives

The Scientific World Journal, 2013
Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (
Hee Bok Chae, Seon Mee Park, Sei Jin Youn   +2 more
doaj   +1 more source

Characterization of ADME properties of [¹⁴C]asunaprevir (BMS-650032) in humans

, 2016
1. Asunaprevir (ASV, BMS-650032), a highly selective and potent NS3 protease inhibitor, is currently under development for the treatment of chronic hepatic C virus infection. This study describes in vivo biotransformation in humans and the identification
Hao Jiang (95017), W. Griffith Humphreys (842751), Bing He (135034), Vinod Arora (842748), Ramaswamy A. Iyer (842752), Jiachang Gong (842746), Thomas Philip (842749), John Easter (842750), Timothy Eley (842747), Wenying Li (842753)   +9 more
core   +1 more source

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

PLoS ONE, 2017
The risk of hepatocellular carcinoma (HCC) development is reduced following viral elimination by interferon therapy in chronic hepatitis C patients. However, the risk in patients treated with interferon-free direct-acting antivirals (DAAs) is unknown. We
Yuko Nagaoki, Michio Imamura, Hiroshi Aikata, Kana Daijo, Yuji Teraoka, Fumi Honda, Yuki Nakamura, Masahiro Hatooka, Reona Morio, Kei Morio, Hiromi Kan, Hatsue Fujino, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Yoshiiku Kawakami, C Nelson Hayes, Daiki Miki, Hidenori Ochi, Kazuaki Chayama   +23 more
doaj   +1 more source

Increase in albumin by daclatasvir/asunaprevir therapy is correlated with decrease in aspartate transaminase

, 2017
ObjectiveTo elucidate the mechanism of an increase in the albumin levels by daclatasvir (DCV)/asunaprevir (ASV) therapy, we assessed the factors associated with an increase in the albumin levels.MethodsWe retrospectively analyzed 125 patients with ...
Kentaro Yoshioka, Takuji Nakano, Toshiki Kan, Naoto Kawabe, Senju Hashimoto, Kazunori Nakaoka   +5 more
core   +1 more source

The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents

Kaohsiung Journal of Medical Sciences, 2017
Direct-acting antiviral agents (DAAs) have been widely used for chronic hepatitis C (CHC) treatment recently. The characteristics of glucose abnormalities after DAAs therapy however, remain elusive.
Jee-Fu Huang, Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Meng-Hsuan Hsieh, Jeng-Fu Yang, Ching-I. Huang, Yi-Hung Lin, Po-Cheng Liang, Zu-Yau Lin, Shinn-Chern Chen, Ming-Lung Yu, Wan-Long Chuang   +12 more
doaj   +1 more source

Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno

, 2017
© 2017 Objectives To assess the impact on the 2015 national health budget of incorporating Daclatasvir/Asunaprevir (DCV / ASV) for the treatment of Hepatitis C genotype 1b (HC1b) in Chile.
Vargas, C., Soza, Alejandro, A. Soza, Giglio, A., Espinoza, M. A., Soza, A., Espinoza Sepúlveda, Manuel Antonio, C. Vargas, Espinoza, MA, Vargas, C, Soza, A, A. Giglio, Giglio, A, M.A. Espinoza   +13 more
core   +1 more source

Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing

, 2016
The discovery of a back-up to the hepatitis C virus NS3 protease inhibitor asunaprevir (2) is described. The objective of this work was the identification of a drug with antiviral properties and toxicology parameters similar to 2, but with a preclinical ...
Paul Falk (1834291), Maria Donoso (3076479), Brian L. Venables (3076482), Luciano Mueller (1629796), Paul M. Scola (1639726), Sing-Yuen Sit (1834315), Huabin Sun (136356), Donna M. Bilder (1834252), Yong-Hae Han (1834264), Richard Rampulla (1601455), Jacques Friborg (715566), Anthony Cocuzza (1834261), Kathy Mosure (1834165), Barbara Zheng (1834270), Li-Qiang Sun (1834282), Danshi Li (1834276), Qian Zhao (217607), Alicia Ng (1442749), Herbert E. Klei (486974), Paul C. Levesque (3076500), Ying-Kai Wang (1834240), Mark I. Cockett (3076488), Dennis Hernandez (1834255), Hua Fang (627909), Jay O. Knipe (1834321), Kevin Kish (1399378), Amy K. Sheaffer (1834249), Eric Mull (3076497), Ny Sin (1834294), Fei Yu (61577), Richard Schartman (2012938), Lucy Sun (448588), Dennis M. Grasela (1834273), Stephen Adams (1780435), Hong Shi (177669), Pirama Nayagam Arunachalam (3076485), James Loy (2611882), Fiona McPhee (414636), Qi Gao (133189), Steven Levine (127461), Jeffrey Tredup (2213062), Chaoqun Chen (354923), Arvind Mathur (144120), Tatyana Zvyaga (1834306), Yan Chen (4308), William Warner (3076491), Bang-Chi Chen (1565908), Nicholas A. Meanwell (362044), Theerthagiri Palani (3076476), Michael W. Sinz (1834258), Jialong Zhu (1834288), Jie Chen (5892), Ramkumar Rajamani (1442725), Alan Xiangdong Wang (1834303), Sivakumar Ganesan (3076494), Stanley D’Andrea (1834246)   +55 more
core   +1 more source